AstraZeneca Announces Positive Results from Benralizumab Phase III Program in Severe Asthma

[Business Wire] – AstraZeneca today announced that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody, was well tolerated and achieved the primary endpoint in two pivotal Phase III registrational trials , demonstrating significant reductions in the annual asthma exacerbation rate compared to placebo.